Watch Live

Tweet TWEET

Acura Pharmaceuticals Provides Update on NEXAFED(R) Launch

Acura Pharmaceuticals Provides Update on NEXAFED(R) Launch 
Over 2,600 Pharmacies Now Selling the Meth-Resistant Pseudoephedrine
Product 
PALATINE, IL -- (Marketwired) -- 09/18/13 --  Acura Pharmaceuticals,
Inc. (NASDAQ: ACUR) today announced its next generation
pseudoephedrine hydrochloride tablet, NEXAFED, is now being sold in
over 2,600 pharmacies nationwide. Since its introduction in December
2012, NEXAFED has become the standard of care in many pharmacies,
including all Fruth Pharmacies and all the independent pharmacies of
Scott County, Tennessee, who stock NEXAFED as their only 30mg
pseudoephedrine product. NEXAFED not only contains the unique
methamphetamine-resistant IMPEDE(R) Technology but also meets a key
Food and Drug Administration human clinical efficacy standard. 
The recent increase in pharmacies stocking NEXAFED can be attributed
to (i) Meijer Pharmacies who are stocking NEXAFED in all their
pharmacies, (ii) the addition of a large regional supermarket chain
based in Florida, and (iii) further distribution gains at independent
pharmacies. Through national and regional wholesalers, Nexafed is
readily available to nearly every pharmacy in the U.S. 
"We're seeing a significant increase in repeat orders from
pharmacies," said J. Bradley Rivet, Vice President, Marketing with
Acura Pharmaceuticals. "We've come to appreciate that once
pharmacists begin recommending NEXAFED and are satisfied with its
effectiveness, they typically become an advocate." 
"The launch of our current NEXAFED formulation continues to progress
well as we prepare our improved IMPEDE 2.0 formulation for market,"
said Robert B. Jones, president and chief executive officer of Acura
Pharmaceuticals. "The pharmacists and chain pharmacies that stock and
recommend our product have reviewed our test results closely and been
very discriminating in the selection of effective products they can
recommend with confidence for their patients." 
For more information about NEXAFED, which is currently distributed
through national and regional drug wholesalers to chain and
independent drugstores nationwide, and for updates on the rollout of
the new IMPEDE 2.0 technology, visit JOIN-FIGHT.COM. 
About NEXAFED(R)
 NEXAFED(R) [pseudoephedrine hydrochloride] is a 30
mg immediate-release abuse-deterrent decongestant. The next
generation pseudoephedrine tablet combines effective nasal congestion
relief with IMPEDE technology, a unique polymer matrix that disrupts
the conversion of pseudoephedrine into the dangerous drug,
methamphetamine. IMPEDE technology forms a thick gel when the tablets
are dissolved in solvents typically used in the pseudoephedrine
extraction or methamphetamine production processes, trapping the
pseudoephedrine or converted methamphetamine to resist its isolation
or purification. 
About Acura Pharmaceuticals, Inc.
 Acura Pharmaceuticals, Inc. is a
specialty pharmaceutical company dedicated to bringing to market safe
and effective products intended to address medication abuse and
misuse. As a leader in abuse-deterrent technology, Acura
Pharmaceuticals has successfully developed a prescription drug
product that addresses abuse and which is licensed to and marketed by
a major pharmaceutical company. Acura Pharmaceuticals is committed to
addressing the needs of local communities by investing in ongoing
research and development to drive improvement in abuse-deterrent
technology. 
Forward Looking Statements
 Certain statements in this press release
constitute "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause our actual results,
performance or achievements to be materially different from any
future results, performance, or achievements expressed or implied by
such forward-looking statements. Forward-looking statements may
include, but are not limited to, the timing of our ability to
successfully develop and launch our next generation NEXAFED Tablets,
the market acceptance of and competitive environment for any of our
products, the willingness of wholesalers and pharmacies to stock
NEXAFED Tablets, expectations regarding potential market share for
our products and the timing of first sales, the adequacy of the
results of the laboratory and clinical studies completed to date, the
sufficiency of our development to meet over-the-counter, or OTC,
Monograph standards as applicable, adverse safety findings relating
to our product candidates, our exposure to product liability and
other lawsuits in connection with the commercialization of our
products, the increasing cost of insurance and the availability of
product liability insurance coverage, and whether our IMPEDE
technology, including our NEXAFED Tablets, will disrupt the
processing of pseudoephedrine into methamphetamine, including whether
NEXAFED will prove resistant to methamphetamine conversion methods
that may be utilized in the future by clandestine methamphetamine
laboratories. In some cases, you can identify forward-looking
statements by terms such as "may," "will," "should," "could,"
"would," "expects," "plans," "anticipates," "believes," indicated,"
"estimates," "projects," "predicts," "potential" and similar
expressions intended to identify forward-looking statements. These
statements reflect our current views with respect to future events
and are based on assumptions and subject to risks and uncertainties.
Given these uncertainties, you should not place undue reliance on
these forward-looking statements. We discuss many of these risks in
greater detail in our filings with the Securities and Exchange
Commission. 
Contacts
Investor Relations:
Pete Clemens
Acura Pharmaceuticals
investors@acurapharm.com
847-705-7709 
MediaRelations:
Kaitlin Bowen
Spectrum
kbowen@spectrumscience.com
202-955-6222 
 
 
Press spacebar to pause and continue. Press esc to stop.